by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
With the ultimate goal of having a cure for multiple myeloma, researchers and clinicians hope to assemble strategies that will incorporate new and ......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
Chimeric antigen receptor (CAR) T-cell therapy can achieve very high response rates in heavily pretreated multiple myeloma, allowing many patients ......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
In the nontransplant setting, continuous therapy may involve a doublet or a triplet regimen as tolerated until disease progression. After the more ......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
Immunomodulatory drugs act through multiple mechanisms, some of which have yet to be fully characterized. In addition to pairings with proteasome i......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
RVd (lenalidomide, bortezomib, and dexamethasone) continues to represent the standard of care even for older patients, for whom other triplets are ......READ MORE
